A novel method for generating an antigen-specific cancer vaccine and immunotherapy has emerged using a DNA vaccine. However, antigen-presenting cells (APCs) have a limited life span, which hinders their long-term ability to prime antigen-specific T cells. Connective tissue growth factor (CTGF) has a role in cell survival. This study explored the intradermal administration of DNA encoding CTGF with a model tumor antigen, human papilloma virus type 16 E7. Mice vaccinated with CTGF/E7 DNA exhibited a dramatic increase in E7-specific CD4 + and CD8 + T-cell precursors. They also showed an impressive antitumor effect against E7-expressing tumors compared with mice vaccinated with the wild-type E7 DNA. The delivery of DNA encoding CTGF and E7 or CTGF alone could prolong the survival of transduced dendritic cells (DCs) in vivo. In addition, CTGF/E7-transduced DCs could enhance a higher number of E7-specific CD8 + T cells than E7-transduced DCs. By prolonging the survival of APCs, DNA vaccine encoding CTGF linked to a tumor antigen represents an innovative approach to enhance DNA vaccine potency and holds promise for cancer prophylaxis and immunotherapy.
Introduction
Cervical cancer is the most frequent neoplasm and has the fifth highest mortality rate among the malignancies in women. [1] [2] [3] Each year it affects half a million women worldwide and cause about 200 000 deaths. Human papilloma viruses (HPVs) have been consistently implicated in causing cervical cancer, especially the highrisk types. [3] [4] [5] [6] An international study revealed that around 50% of cervical cancer cases contained HPV type 16 (HPV16) in their specimens. 3 HPV infection precedes cervical intraepithelial neoplasia and thus infection with HPV16 produces the highest risk of developing cervical cancer. 3 An ideal cancer treatment should be able to eradicate systemic tumors at multiple sites in the body and should have the ability to discriminate between neoplastic and non-neoplastic cells. The present available forms of treatment for cervical cancer, for example surgery, radiation therapy and chemotherapy, 7, 8 are all cytoreductive treatment modalities. This means that in addition to cancerous cells, healthy cells are also destroyed in the process. In this regard, antigen-specific cancer immunotherapy would be an attractive approach for cancer treatment. 9, 10 Intradermal administration of DNA vaccines using a gene gun can be used to efficiently deliver genes of interest into professional antigen-presenting cells (APCs) in vivo for cancer vaccine and immunotherapy. 11 The skin contains numerous bone marrow-derived APCs (called Langerhans cells) that are able to move through the lymphatic system from the site of injection to draining lymph nodes, where they prime antigen-specific T cells. 12 Previously, the gene gun approach was used to test strategies capable of routing model antigens to desired subcellular compartments such as endosome and centrosome, and enhance antigen processing and presentation to T cells. [13] [14] [15] Connective tissue growth factor (CTGF) is a cysteinerich protein originally identified in a conditioned medium of human umbilical vein endothelial cells. 16 Recently, CTGF has been shown to inhibit apoptosis of chicken embryo fibroblasts 17 and human rhabdomyosarcoma cells. 18 It has also been demonstrated to promote endothelial cell survival. 19 CTGF could promote differentiation through a p38 mitogen-activated protein kinase and proliferation through a p44/42 MAPK/extracellularsignal regulated kinase in chondrocytes. 20 CTGF can also promote the acquisition of the apoptosis-resistant phenotype that may be similar to those of IGF-II in skeletal myoblasts. 21, 22 In this study, we tested CTGF, the potential antiapoptotic molecule, for its ability to enhance survival of dendritic cells (DCs) and E7-specific CD8 + T-cell immune responses, when linked to E7 DNA. We chose HPV16 E7 as a model antigen, because HPVs, particularly HPV16, are associated with a majority of cervical cancers, while E7 is essential for the induction and maintenance of cellular transformation. Effective vaccines against E7 can potentially be used to control HPV infections and HPV-associated lesions. By examining E7-specific immune responses, antitumor effects, survival of DNA-transfected DCs and the ability of DNA-transfected DCs to activate an E7-specific T cell line, we demonstrated that a CTGF/E7 chimeric DNA vaccine could generate a dramatic increase in E7-specific CD4 + and CD8 + T-cell precursors. It also has an impressive antitumor effect against E7-expressing tumors by prolonging the survival of transduced DCs in vivo. An antiapoptotic strategy could increase the immunologic responses and create a more potent antitumor effect.
Results
Vaccination with DNA encoding CTGF linked to E7 significantly enhanced the E7-specific T-cell immunities To determine whether CTGF could enhance E7-specific T-cell-mediated immune responses in mice when linked to the E7 DNA vaccine, we performed intracellular cytokine staining with flow cytometry analysis to characterize E7-specific CD4 + and CD8 + T-cell precursors. The representative figures of E7-specific CD8 + T precursors in various vaccinated groups by flow cytometry analysis are shown in Figure 1a . Figure 1b shows that vaccination with CTGF/E7 DNA generated higher frequencies of E7-specific interferon (IFN)-g-secreting CD8
+ T-cell precursors when compared to mice vaccinated with the other DNA-vaccinated groups (14.1±2.1 for the 'naïve' group, 15.0±1.4 for the 'no insert' group, 15.0 ± 2.8 for the 'wild-type E7' group, 12.0±2.1 for the 'CTGF' group, 844.0±35.5 for the 'CTGF/E7' group, Po0.01). Mice vaccinated with (Figure 1c ). However, mice vaccinated with CTGF/E7 DNA vaccine revealed significantly higher numbers of E7-specific interleukin-4-secreting CD4 + T-cell precursors than the other groups (18.0±5.0 for the naïve group, 14.5±3.5 for the no insert group, 15.0 ± 2.8 for the wild-type E7 group, 23.0 ± 6.0 for the CTGF group, 178.0±15.0 for the CTGF/E7 group, Po0.01) (Figure 1d ).
We also evaluated whether the CTGF/E7 DNA vaccine would influence the percentages of B lymphocytes. No difference in the percentages of B lymphocytes could be observed between the naïve and DNAvaccinated groups (Figure 2a) .
Enzyme-linked immunosorbent assay (ELISA) was carried out to determine whether CTGF/E7 DNA could enhance the E7-specific antibody response in vaccinated mice. The titers of anti-E7 antibodies generated by CTGF/E7 DNA vaccine were significantly higher than those by the other DNA vaccines (0.167±0.015 for the naïve group, 0.163 ± 0.016 for the no insert group, 0.179±0.025 for the wild-type E7 group, 0.184±0.020 for the CTGF group, 0.176 ± 0.021 for E7 mixed with the CTGF group, 1.048±0.104 for the CTGF/E7 group, 1:100 dilution, Po0.01) (Figure 2b) . However, the titers of anti-E7 antibodies in mice vaccinated with CTGF/E7 DNA vaccine with CD4 depletion group (0.532 ± 0.018, 1:100 dilution) significantly decreased as compared with those with CD8-depletion group (1.829 ± 0.028, 1:100 dilution), NK1.1-depletion group (1.827 ± 0.043, 1:100 dilution), or without antibody-depletion group (1.872±0.028, 1:100 dilution, Po0.01, one-way analysis of variance) (Figure 2c ).
Our results reveal that the physical linkage of CTGF to E7 could enhance the E7-specific helper and cytotoxic T-cell immunities and E7-specific antibody responses.
Vaccination with CTGF/E7 DNA enhanced tumor protection in mice challenged with an E7-expressing tumor cell line
To determine whether the observed enhancement of E7-specific CD8 + T-cell response translated into a significant E7-specific protective antitumor effect, we performed an in vivo tumor-protection experiment. As shown in Figure 3a , when challenged with TC-1 tumor cells, 100% of mice receiving CTGF/E7 DNA vaccination remained tumor-free even 60 days after the challenge. In comparison, all mice vaccinated with the wild-type E7 DNA developed tumors within 14 days. Thus, CTGF may protect vaccinated mice against a lethal challenge with E7-expressing tumor cells, when it is linked to the E7 antigen in a DNA vaccine.
Treatment with CTGF/E7 led to a significant reduction of pulmonary tumor nodules in vaccinated mice
We further assessed the therapeutic potential of each vaccine by performing an in vivo tumor treatment experiment using the lung hematogenous spread model described by Liao et al. 23 The representative pulmonary tumor nodules are shown in Figure 3b . As shown in These data indicate that CTGF when linked to the E7 antigen could generate more potent preventive and therapeutic effects than the wild-type E7 DNA constructs in both subcutaneous and lung hematogenous spread models.
Only CD8
+ T cells were essential for the antitumor effect generated by CTGF/E7 DNA To determine the subset of lymphocytes important for the antitumor effect, we performed in vivo antibodydepletion experiments. 13 As shown in Figure 4 , all naïve mice and mice depleted of CD8 + T cells grew tumors within 14 days after the tumor challenge. In contrast, all of the nondepleted mice and all of the vaccinated mice depleted of CD4 + T cells or NK1.1 cells remained tumorfree even 60 days after the tumor challenge.
These results suggest that CD8 + T cells are important and essential for the antitumor immunity generated by the CTGF/E7 DNA vaccine. Improved survival of DNA-transfected DCs in inguinal lymph nodes of mice vaccinated with CTGF/E7/GFP DNA To find out whether the in vivo antiapoptotic phenomenon of CTGF/E7 DNA could also be observed in vivo to enhance the E7-specific immunity, we used green fluorescent protein (GFP) linked to E7 as a fluorescent tag to identify DNA-transfected DCs in the inguinal lymph nodes. Inguinal lymph nodes were collected from vaccinated mice at 1 and 5 days after gene gun vaccination. CD11 + cells with DC size and granular characteristics were gated as DCs, as reported previously. 22 As shown in Figure 6a , there was no significant difference in numbers of CD11c and GFP-positive cells in the inguinal lymph nodes at day 1 after vaccination with various DNA constructs. On day 5 after gene gun vaccination, however, a greater percentage of GFP + CD11c
+ cells was observed in lymph nodes of + cells were enriched, incubated with an E7-specific CD8 + T cell line and intracellular cytokine staining and flow cytometry analysis were performed to determine the number of E7-specific IFN-g-secreting CD8
+ T cells. The data collected from all of the above experiments are from one experiment representative of the two performed. CTGF, connective tissue growth factor; IFN, interferon.
DNA vaccine linking CTGF with HPV16 E7 antigen W-F Cheng et al CTGF/E7/GFP DNA-vaccinated mice as compared with lymph nodes collected from mice vaccinated with E7/GFP or only GFP DNA constructs (0.085 ± 0.005 for the naïve group, 0.160±0.006 for the GFP group, 0.190 ± 0.007 for the E7/GFP group, 0.455 ± 0.010% for the CTGF/E7/GFP, Po0.001, one-way analysis of variance) (Figure 6a) .
We further assayed for the apoptotic cells in GFP + CD11c + cells derived from the draining lymph nodes of various vaccinated mice by staining for annexin V followed by flow cytometry analysis. As shown in Figure 6b , at day 5, mice vaccinated with DNA encoding CTGF/E7/GFP DNA demonstrated a significantly lower percentage of apoptotic cells when compared with mice vaccinated with E7/GFP or GFP only (49.8 ± 3.7 for the naïve group, 49.5±3.9 for the GFP group, 46.9±4.2 for the E7/GFP group, 24.4 ± 1.7% for the CTGF/E7/GFP, Po0.001, one-way analysis of variance).
Our results suggest that the administration of CTGF/ E7/GFP DNA, which generated an antiapoptotic function, prolonged the survival of DNA-transfected DCs in vivo.
CD11c-enriched cells from mice vaccinated with CTGF/E7/GFP DNA enhanced the activation of an E7-specific CD8 + T cell line
We evaluated whether these CTGF/E7-transfected CD11c-enriched cells with prolonged life span from the inguinal lymph nodes of the CTGF/E7/GFP DNAvaccinated mice had the ability to stimulate INF-g secretion from an E7-specific CD8 + T cell line. These CD11c-enriched cells were isolated 1 or 5 days after the last DNA vaccination and were incubated with an E7-specific T cell line. As shown in Figure 6c , CD11c-enriched cells isolated from mice vaccinated with CTGF/ E7/GFP DNA were more effective in activating the E7-specific CD8 + T cell line to secrete IFN-g compared with E7/GFP or GFP-only DNA vaccine, particularly at day 5 (18.0±4.2 for the no insert group, 36.0±4.9 for the GFP group, 38.0 ± 5.6 for the E7/GFP group, 373.0 ± 15.5 for the CTGF/E7/GFP, Po0.001).
These in vivo results are consistent with the notion that DNA-transfected DCs from mice vaccinated with CTGF/ E7/GFP DNA could enhance the activation of E7-specific CD8 + T cells via the antiapoptotic function of CTGF.
Discussion
In this study, we demonstrated that linking of HPV16 E7 antigen to CTGF DNA can significantly enhance the potency of an E7-expressing DNA vaccine. CTGF/E7 DNA elicited strong E7-specific CD8 + T-cell immune responses (Figure 1b) , generated a significant CD8 + T-cell-dependent protective effect against subcutaneous HPV16 E7-expressing tumors (Figures 3a and 4) , and was useful in the treatment of lethal pulmonary tumor nodules (Figure 3c ). DC life could be prolonged by inhibiting apoptosis using CTGF/E7 DNA, and not wild-type E7 DNA, resulting in an increased quantity of longer-lived DCs in the draining lymph nodes ( Figure 6 ). Thus, our data supported our hypothesis that linking of CTGF to E7 creates a better vaccine than either E7 or CTGF via the antiapoptotic mechanism. CTGF/E7 chimeric DNA vaccine enhances antigenspecific T-cell immunity by an antiapoptotic mechanism. Our in vivo observations showed that in vivo CTGF/E7-transfected DCs had longer life spans than in vivo E7-transfected DCs (Figure 6b ). In addition, these CTGF/E7-transfected DCs stimulated higher numbers of E7-specific CD8 + T cells than E7-transfected DCs in vivo (Figure 6c ). Our explanation is that the CTGF/E7 chimeric molecule may create larger numbers of APCs in vivo by its antiapoptotic function than wild-type E7 did. These E7-specific APCs transfected by CTGF/E7 enhanced higher E7-specific T-cell immunity and generated potent preventive and therapeutic effects of the E7-specific tumor. Many molecules, such as Bcl-2, Bcl-XL or serine protease inhibitor-6 successfully enhance antigen-specific immunity by their antiapoptotic ability. 24, 25 However, Bcl-2 and Bcl-XL have been shown to be oncogenes, which are not suitable for transduction to enhance immune responses in vivo.
Connective tissue growth factor secreted by fibroblasts for multiple purposes is more likely to be utilized in clinical applications for its antiapoptotic strategy. 26 Its presence has been shown to be a survival factor for different cell types. 27, 28 Previous studies have demonstrated that CTGF may also be a useful therapeutic agent in human rhabdomyosarcoma. 18 Disrupting CTGF expression using CTGF-neutralizing antibodies could enhance the apoptosis of rhabdomyosarcoma cells and inhibit the angiogenesis. This evidence suggests that CTGF may have a key role in tumor progression because of its antiapoptotic function. CTGF's ability to inhibit apoptosis in tumor cells may be one of the safety concerns that make the CTGF/E7 chimeric DNA vaccine recommendable. Our results revealed that mice vaccinated with CTGF DNA only would not promote tumorigenesis as compared with those vaccinated with wild-type E7 DNA or naïve mice in the tumor treatment experiments (Figure 3c ). This implies that a CTGF/E7 chimeric DNA vaccine can generate potent antitumor effects, and not tumorigenic effects.
E7-specific antibody titers were significantly enhanced by CTGF/E7 vaccination. CTGF/E7 DNA vaccine could enhance the antibody response and interleukin-4-secreting CD4
+ helper T-cell precursors in vaccinated mice (Figures 1d and 2b) . CTGF can be secreted into the stroma to work for the endocrine or paracrine functions as a chemotactic and mitogenic factor on fibroblasts to induce wound healing. 29 It seems that the CTGF/E7 chimeric protein could enhance the anti-E7 antibody responses via the Th2 cell pathway in our observation. Although the overall percentages of B cells was not altered between vaccinated groups (Figure 2a) , we still cannot rule out the possibility that the percentage of antibody-secreting plasma cells may be enhanced by the CTGF/E7 vaccine. It would be interesting to pursue further research to find out how CTGF enhances humoral immunity. Although antibody-mediated responses have not been shown to have an important role in controlling HPV-associated malignancies, antigen-specific antibodies are significant in other tumor models, such as the breast cancer model with the HER-2/neu antigen. So the chimeric CTGF vaccine strategy may be used to generate antibodies that perform on tumor cells.
Our in vivo antibody-depletion experiment was consistent with the concept that CD8 + T cells are the key DNA vaccine linking CTGF with HPV16 E7 antigen W-F Cheng et al players in gene gun-mediated CTGF/E7 DNA vaccination ( Figure 4 ). Our data showed that CD8 + T cells are required in the effector phase of antitumor immunity. In contrast, the depletion of CD4 + or NK1.1 + cells did not decrease antitumor immunity generated by CTGF/E7 DNA. Such phenomena could also be observed in the other E7-chimeric DNA molecules, such as calreticulin/ E7, E7/HSP70, VP22/E7 or g-tubulin/E7, 13, 15, 30, 31 although they enhanced antigen-specific immunity in different ways.
DNA vaccine with combined strategies generates significantly higher antitumor immunity than those with a single strategy. Previous studies have demonstrated that vaccination with DCs transfected with BAK/BAX short interfering RNA can generate a stronger therapeutic antitumor effect in vaccinated mice compared with a control short interfering RNA. 32 These data indicate that administering antigen peptide-loaded DCs transfected with BAK/BAX short interfering RNA prolongs the life of the DCs and enhances antigen-specific CD8 cytotoxic killing effects. In this study, we also observed that mice vaccinated with DNA encoding E7/GFP mixed with DNA encoding CTGF demonstrate a significantly lower percentage of apoptotic cells in CD11c+ GFP+ cells derived from the draining lymph nodes. Our results suggest that the increase in the number of antigen-expressing DCs in lymph nodes may contribute to the enhancement of E7-specific T-cell activation. However, such qualitative changes may result in vaccination with DNA encoding antiapoptotic factors. Mice vaccinated with calreticulin/E7 combined with CTGF DNA have significantly enhanced antitumor effects compared with those vaccinated with calreticulin/E7 only (data not shown). These data indicate that the antitumor effects of DNA vaccine are more potent when combined with different strategies.
In summary, this study demonstrates that linkage of CTGF to the HPV16 E7 antigen can significantly elicit strong E7-specific CD8 + T-cell immune responses and generates significant CD8 + T-cell-dependent protective effects against subcutaneous HPV16 E7-expressing tumors that can effectively treat lethal pulmonary tumor nodules. CTGF/E7 chimeric DNA may prolong the life span of CTGF/E7-transfected DCs to induce higher numbers of E7-specific T-cell precursors in vivo. The antiapoptosis strategy can also be synergistically applied in combination with other DNA vaccines. The promising results of this study will encourage the application of the combined strategies to target other cancers or infectious diseases with known antigens.
Materials and methods

Plasmid DNA constructs and preparation
To generate pcDNA3-CTGF, CTGF was first amplified by PCR using human placenta cDNA as the template and a set of primers: 5 0 -CCGCTCGAGAGGAGCCCAGCTAT GAACTC-3 0 and 5 0 -CCGGAATTCGACCAGAAGAAG GAATGCCC-3 0 . The amplified product was then cloned into the XhoI/EcoRI sites of pcDNA3 vector (Invitrogen Corp., Carlsbad, CA, USA). To generate pcDNA3-CTGF/ E7, E7 was generated as described in a previous study 23 and cloned into the HindIII sites of pcDNA3-CTGF to generate pcDNA3-CTGF/E7. To generate pcDNA3-CTGF/E7/GFP, pcDNA3-CTGF/E7 was first digested by the restriction enzyme HindIII. The GFP fragment was obtained from plasmid pcDNA3-E7/GFP by EcoRI/NotI digestion. The DNA fragment was then filled in and ligated into CTGF/E7 to generate the desired plasmid, which was confirmed by sequencing.
Cell line
The production and maintenance of TC-1 tumor cells have already been described in a previous study. 33 In brief, HPV16 E6, E7 and ras oncogene were used to transform primary C57BL/6 lung epithelial cells from mice to generate TC-1. On the day of tumor challenge, tumor cells were collected by trypsinization, washed twice with 1 Â Hanks buffered salt solution, and resuspended in the buffer to the concentration designated for injection.
A b cells transfected with various DNA were lysed in an immunoprecipitation assay buffer containing 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl 2 , 1 mM CaCl 2 , 1% NP40, 10% glycerol, 1 mg/ml BSA, 20 mM Tris pH 8.0 and 2 mM orthovanadate, and were analyzed as described previously. 5 Briefly, 50 mg of cell lysates were resolved on an SDS-containing 12% polyacrylamide gel. They were transferred to polyvinylidene difluoride nylon membranes (Millipore, Bedford, MA, USA) and probed with antibodies specific to E7 (Zymed, San Francisco, CA, USA) or b-actin (Chemicon International Inc., Temecula, CA, USA). The membrane was then probed with either horseradish peroxidase-conjugated goat-anti-mouse or goat-anti-rabbit antibody. The specific bands were visualized by an ECL (enhanced chemiluminescence) western blot system (Amersham, Buckinghamshire, England).
Mice
Six-to 8-week-old female C57BL/6J mice were purchased and kept in the animal facility of the school of Medicine, National Taiwan University. All of the animal procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals. In all the following experiments, the mice were divided into groups of five mice each.
DNA vaccination
Preparation of DNA-coated gold particles and gene gun particle-mediated DNA vaccinations were performed using a helium-driven gene gun, according to a protocol we used in previous research.
14 Respective DNA-coated gold particles were delivered to the shaved abdominal region of mice with a 50 psi discharge pressure of helium.
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Intracellular cytokine staining and flow cytometry analysis
In the first experiment, the mice were immunized with 2 mg of the various DNA vaccines and received a booster with the same regimen 1 week later. Splenocytes were harvested 1 week after the last vaccination. Before intracellular cytokine staining, 3.5 Â 10 5 pooled splenocytes from each vaccination group were incubated for 16 h with either 1 mg ml À1 of E7 peptide (aa 49-57) containing an MHC class I epitope 34 for detecting E7-specific CD8 + T-cell precursors or 10 mg ml À1 of E7 peptide (aa 30-67) containing an MHC class II epitope 35 for detecting E7-specific CD4 + T-cell precursors. Golgistop (Pharmingen, San Diego, CA, USA) was added 6 h before harvesting the cells, which were first stained with PE-CD8 or CD4 antibody (Pharmingen), and then subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit, according to the manufacturer's instructions (Pharmingen). Intracellular cytokine staining for fluorescein isothiocyanate-IFN-g (Pharmingen), interleukin-4 (Biolegend, San Diego, CA) or immunoglobulin isotype control antibody (rat IgG1) (Pharmingen), as well as flow cytometry analysis, were performed using conditions described previously. 36 In the second experiment, the splenocytes were stained first with fluorescein isothiocyanate-CD3 and PE-CD19 antibodies (Pharmingen) and analyzed as already described to identify the percentages of B lymphocytes (CD3(À)CD19(+)).
Enzyme-linked immunosorbent assay for anti-E7 antibody
In the first experiment, mice were immunized with 2 mg of the various DNA vaccines and received a booster with the same regimen 1 week later. Sera were prepared from the mice 14 days after their last immunization. To detect HPV16 E7-specific antibodies in the sera, direct ELISA was used as described previously. 37 The ELISA plate was read with a standard ELISA reader at 450 nm.
In the second experiment, mice were immunized with 2 mg of the CTGF/E7 DNA vaccine with a gene gun, boosted 1 week later, and received respective antibody to deplete the CD4, CD8 and NK1.1 lymphocytes. The monoclonal antibody GK1.5 was used for CD4 depletion, 38 2.43 was used for CD8 depletion 39 and PK136 was used for NK1.1 depletion. 40 Depletion was terminated on day 14 after the last immunization. Sera were prepared from the mice 14 days after their last immunization. To detect HPV16 E7-specific antibodies in the sera, direct ELISA was used as described above.
In vivo tumor protection experiments
For the first tumor protection experiments, the mice either received no vaccination or were immunized with 2 mg per mouse of various DNA vaccines with a gene gun. At 1 week later, the mice were boosted with the same regimen as the first vaccination. One week after the last vaccination, they were subcutaneously challenged with 5 Â 10 4 cells per mouse of TC-1 tumor cells in the right leg. The mice were monitored for evidence of tumor growth by palpation and inspection twice a week until they were sacrificed on day 60.
In vivo antibody depletion experiments
In vivo antibody depletions were performed as in a previous study. 41 Briefly, the mice were vaccinated with 2 mg per mouse of CTGF/E7 DNA with a gene gun, boosted 1 week later and challenged with 5 Â 10 4 cells per mouse of TC-1 tumor cells. Injection of respective antibody was started 1 week before tumor challenge and terminated on day 40 after the tumor challenge. The mice were monitored for evidence of tumor growth by palpation and inspection twice a week until they were killed on day 60.
In vivo tumor treatment experiments
For the first in vivo tumor treatment experiment, the mice were injected with 5 Â 10 4 cells per mouse of TC-1 tumor cells via the tail vein as described earlier. 42 Two days after tumor challenge, the each mouse received 16 mg of no insert DNA, E7 DNA, CTGF DNA or CTGF/E7 DNA by a gene gun. This was followed by a booster with the same regimen every 7 days for 4 weeks (a total 64 mg DNA). Mice receiving no vaccination were used as a negative control. The mice were sacrificed and their lungs were explanted on day 28. Pulmonary tumor nodules in each mouse were evaluated and counted by experimenters who were blind to the sample identities.
In vitro apoptotic assays 
Preparation of CD11c
+ cells in the inguinal lymph nodes from vaccinated mice C57BL/6J mice received multiple inoculations of nonoverlapping intradermal administration with a gene gun on the abdominal region. Gold particles used for each inoculation were coated with 1 mg of pcDNA3 encoding GFP, E7/GFP or CTGF/E7 DNA. The pcDNA3 with no insert was used as a negative control. Inguinal lymph nodes were harvested from vaccinated mice 1 or 5 days after vaccination with a gene gun. A single-cell suspension from isolated inguinal lymph nodes was prepared. CD11c + cells were enriched from lymph nodes using CD11c (N418) micro-beads (Miltenyi Biotec, Auburn, CA, USA). The percentage of CD11c + cells was characterized by flow cytometry analysis using PE-conjugated anti-CD11c antibody (Pharmingen). GFP-positive cells were analyzed by flow cytometry analysis using a previously described protocol. 
Activation of E7-specific CD8+ T cell line by CD11c-enriched cells
Mice were vaccinated and CD11c + -enriched cells were collected as described above. CD11c-enriched cells (2 Â 10 4 ) were incubated with 2 Â 10 6 of the E7-specific CD8 + T cell line for 16 h. The cells were then stained for both surface CD8 and intracellular IFN-g and analyzed with flow cytometry analysis as described above.
Statistical analysis
All data were expressed as mean ± s.e.m. or mean ± s.d. and were representative of at least two different experiments. Data for intracellular cytokine staining with flow cytometry analysis and tumor treatment experiments were evaluated by analysis of variance. Comparisons between individual data points were made using the Student's t-test. In the tumor protection experiment, the principal outcome of interest was the time it took for the tumor to develop. The event time distributions for different mice were compared using the Kaplan and Meier and log-rank analyses. A P-value o0.05 was considered statistically significant.
